Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Gastrointestinal 3Head & Neck 2Genitourinary 2Thoracic 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Stomach Neoplasms 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 24Nivolumab 7Early Intervention, Educational 7Methods 6durvalumab 5aldesleukin 5Trastuzumab 5Paclitaxel 5Fulvestrant 5Carboplatin 5atezolizumab 4Surveys and Questionnaires 4Patient Navigation 4Docetaxel 4Cyclophosphamide 4Biopsy 4fludarabine 3Mass Screening 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Interleukin-2 3Gene Expression Profiling 3Fluorouracil 3Educational Status 3Bevacizumab 3tremelimumab 2spartalizumab 2sargramostim 2palbociclib 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Adoptive Transfer × Breast × Clear all
NCT05483491 2025-03-30

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Rutgers, The State University of New Jersey

Phase 1 Recruiting
30 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Lung Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡